• All

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

Asgard Therapeutics today announces the publication of key proof-of-concept data supporting its lead program, AT-108, in the high-impact, peer-reviewed journal, Science.

Read more

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

Asgard Therapeutics today announced it selected Exothera S.A. (“Exothera”), a leading provider of nucleic acids and viral vector development and manufacturing services, for process development up to clinical Phases I/II manufacturing of its candidate AT-108.

Read more

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

Asgard Therapeutics today announce a €30 million Series A financing. The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

Read more

Asgard Therapeutics to present positive in vivo efficacy data with AT-108 as monotherapy at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting 

Asgard Therapeutics announces today the presentation of a poster showcasing positive in vivo data. These data will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will take place in San Diego, California November 1-5, 2023.

Read more

Asgard Therapeutics Strengthens Scientific Advisory Board with Two Appointments

Asgard Therapeutics proudly announces the addition of Dr. Ulrich Lauer, MD, and Dr. Aurélien Marabelle, MD PhD to its Scientific Advisory Board (SAB) during its second SAB annual meeting. The addition of these two leading experts in clinical immuno-oncology is a timely complement to Asgard's SAB, given the recent milestone of achieving preclinical proof-of-concept to AT-108 lead program.

Read more

CEO Cristiana Pires receives 2022 RFS Award for publication in Cellular Reprogramming journal

Asgard's Therapeutics CEO Cristiana Pires has been honored with the prestigious 2022 annual Rosalind Franklin Society (RFS), in partnership with Mary Ann Libert, Inc., publisher, Award in Science for her publication in Cellular Reprogramming journal, co-authored with Filipe Pereira, recognizing exceptional contributions of women and underrepresented minority scientists, physicians, and engineers.

Read more

Asgard Therapeutics announces publication on direct reprogramming of cancer cells to force antigen presentation, in collaboration with Lund University

Asgard Therapeutics is proud to announce the publication in Science Immunology demonstrating reprogramming of over 60 mouse and human tumors cells across a broad spectrum of tumor types into functional antigen-presenting cells.

Read more

Cristiana Pires, the CEO, provides an exclusive interview as the winner of the Årets Nybyggare award in the category of Årets Nystart in the South region of Sweden

Our CEO, Cristiana Pires delivers an engaging interview, delving into the entrepreneurial journey of herself and the co-founders of Asgard Therapeutics, Fábio Fiúza Rosa and Filipe Pereira. This insightful interview recognizes their prestigious award of the Årets Nybyggare (Settler of the Year) in 2022 in the category of Årets Nystart in the South region of Sweden.

Read more
Page 1 of 5